Newsletter Fall 2023

_{MISSISSIPPI CANCER REGISTRY}

_{SEPTEMBER 2023}

_{VOLUME 18 ISSUE 3}

Coding Tips for Cancer of the Testies

Presented by Jim Hofferkamp, Testicular Cancer Workshop, sponsored by The CDC used with permission

Set of Rules “Other Sites” used is based on date of diagnosis

• Tumors diagnosed 01/01/2007 through 12/31/2022: Use 2007 MPH

Rules and 2007 General Instructions

• Tumors diagnosed 01/01/2023 and later: Use the 2023 Solid Tumor

Rules and Solid Tumor General Instructions

• Testis: An original tumor diagnosed before 1/1/2023 and a

subsequent tumor diagnosed 1/1/2023 or later in the same primary

site: Use the 2023 Solid Tumor Rules and Solid Tumor General

Instructions

Lymphovascular Invasion (LVI)

• Record presence or absence of LVI from:
• Path report or medical documentation (path report has priority)
• Any primary tumor specimen: biopsy or resection
• Important because LVI can upstage testis from AJCC T1 to T2(LVI does not affect Summary Stage)
• Code 0 for in situ, LVI is not present/identified, and when there is no residual after neoadjuvant therapy and no LVI on bx

Code 1 when:

• LVI or one of its synonyms (list below is not exhaustive) is present:
• Angiolymphatic invasion
• Blood vessel invasion
• Lymph vascular emboli
• Lymphatic invasion
• Lymphvascular invasion
• Vascular invasion
• Lymphovascular space invasion

Code 9 when:

• No microscopic examination of primary tumor
• Primary site specimen is cytology or FNA
• Bx is only a very small tissue sample
• Not possible to determine if LVI is present
• Pathologist states specimen is insufficient to determine LVI
• LVI not mentioned in pathology report or other sources
• Primary site unknown
• Ambiguous terminology used

AJCC Cancer Staging Manual

Cases with a diagnosis date of 01/01/2018 and forward should be staged using AJCC 8th Edition Can-cer Staging Manual. The 3rd printing 2018 Edition is now available.

Please visit https://cancerstaging.org/references-tools/deskreferences/Pages/8EUpdates.aspx# for all 8th Edition updates and corrections. For all other information, visit https://cancerstaging.org/Pages/ de-fault.aspx.

Summary Stage 2018

The 2018 version of Summary Stage applies to every site and/or histology combination, including lym-pho-mas and leukemias. Summary Stage uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. The Summary Stage 2018 manual is available at https://seer.cancer.gov/tools/ssm/.

Site Specific Data Items (SSDI)

Site Specific Data Items (SSDI) are similar to the Site Specific Factors (SSF) collected with Collabora-tive Stage. These data items are specific to certain site/histology combinations. For example, the SSDI’s for breast will be used to collect information such as estrogen receptor status, progesterone receptor status, Her2 status, Nottingham grade, and additional information related to primary tumors of the breast. The in-formation collected in these data items are specific to breast. The SSDI manual is available at https:// apps.naaccr.org/ssdi/list/.

Grade

Beginning with cases diagnosed in 2018 grade information will be collected in three fields; Clinical Grade, Pathological Grade, and Post-Therapy Grade. Within the Grade Manual you will find definitions for the three new grade data items, coding instructions, and the site/histology specific grade tables. The Grade manual is available at https:// www.naaccr.org/SSDI/Grade-Manual.pdf?v=1527859766.

SEER Hematopoietic and Lymphoid Neoplasm Database

This provides data collection rules for hematopoietic and lymphoid neoplasms for 2010+.The SEER Hema-topoietic and Lymphoid Neoplasm manual is available at

https://seer.cancer.gov/tools/heme/ Hematopoietic_Instructions_and_Rules.pdf.

Solid Tumor Coding Manual

Use the 2018 Solid Tumor coding rules to determine the number of primaries to abstract and the his-tology to code for cases diagnosed 2018 and forward. The Solid Tumor coding rules replace the 2007 Multiple Pri-ma-ry and Histology( MP/H) Rules. The manual is available at https://seer.cancer.gov/tools/solidtumor/. The change log contains updates made to the FINAL module sections. This does not include changes made to the drafts.

STORE Manual

The STORE Manual has replaced the FORDS Manual. The STORE is now available at https:// www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals.

Director UMMC & MCR: Deirdre Rogers, dbrogers@umc.edu

MCR Manager: Angel Davis, adavis6@umc.edu

Clinical Systems Analyst-Intermediate: Tresheena Boyd, tboyd@umc.edu

Data Quality Analyst–Trainer: Lisa Hamel, lhamel@umc.edu

Data Quality Analyst-Auditor: April Wright, ahuggins@umc.edu

Cancer Registrars:                                                                                       

Stacy Major, semajor@umc.edu                                                                                                                    

Laken A. Frederick, lfrederick@umc.edu

Madeline N. Hall, mnhall@umc.edu

Mallory R. Israel, misrael@umc.edu

Makaila Johnson, mjohnson41@umc.edu

Administrative Assistant:

Michelle R Smith, mrsmith2@umc.edu 

University of MS Medical Center

2500 North State Street

Jackson, MS 39216

Phone: 601-815-5482

Fax: 601-815-5483